Patterns of antifungal prophylaxis
| . | None . | Micafungin . | Azole . | P . |
|---|---|---|---|---|
| AML setting | .0714 | |||
| Newly diagnosed (n = 55) | 18 (33) | 24 (44) | 13 (24) | |
| r/r (n = 64) | 7 (11) | 25 (39) | 32 (50) | |
| Patient age, y | .0426 | |||
| ≤65 (n = 41) | 5 (12) | 13 (32) | 23 (56) | |
| >65 (n = 78) | 20 (26) | 32 (41) | 26 (33) | |
| HMA type and schedule | .5194 | |||
| Decitabine | ||||
| 5 d (n = 49) | 11 (22) | 21 (43) | 17 (35) | |
| 10 d (n = 54) | 9 (17) | 20 (37) | 25 (46) | |
| Azacitidine (n = 16) | 5 (31) | 4 (25) | 7 (44) |
| . | None . | Micafungin . | Azole . | P . |
|---|---|---|---|---|
| AML setting | .0714 | |||
| Newly diagnosed (n = 55) | 18 (33) | 24 (44) | 13 (24) | |
| r/r (n = 64) | 7 (11) | 25 (39) | 32 (50) | |
| Patient age, y | .0426 | |||
| ≤65 (n = 41) | 5 (12) | 13 (32) | 23 (56) | |
| >65 (n = 78) | 20 (26) | 32 (41) | 26 (33) | |
| HMA type and schedule | .5194 | |||
| Decitabine | ||||
| 5 d (n = 49) | 11 (22) | 21 (43) | 17 (35) | |
| 10 d (n = 54) | 9 (17) | 20 (37) | 25 (46) | |
| Azacitidine (n = 16) | 5 (31) | 4 (25) | 7 (44) |
Data are n (%).